The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 18, 2019

Filed:

Mar. 16, 2016
Applicant:

Mireca Medicines Gmbh, Tubingen, DE;

Inventors:

Per Ekström, Lund, SE;

François Paquet-Durand, Tübingen, DE;

Pieter Jaap Gaillard, Leiden, NL;

Valeria Marigo, Modena, IT;

Hans-Gottfried Genieser, Lemwerder, DE;

Andreas Rentsch, Bremen, DE;

Dragana Trifunovic, Tübingen, DE;

Ayse Sahaboglu Tekgoz, Tübingen, DE;

Assignee:

Mireca Medicines GmbH, Tübingen, DE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/127 (2006.01); A61K 9/00 (2006.01); A61K 31/708 (2006.01);
U.S. Cl.
CPC ...
A61K 9/1271 (2013.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 31/708 (2013.01); Y02A 50/411 (2018.01); Y02A 50/414 (2018.01); Y02A 50/422 (2018.01); Y10S 977/773 (2013.01); Y10S 977/906 (2013.01); Y10S 977/907 (2013.01);
Abstract

The invention relates to means and methods of targeted drug delivery of therapeutic agent to and across the blood-ocular barrier. In particular, the invention relates to cyclic guanosine-3', 5′-monophosphate analogs as therapeutic agent for treating retinal diseases. The cGMPSs targeted to the blood-ocular barrier by glutathione-based ligands that facilitate the specific binding to and enhanced internalization by glutathione transporters present on the blood-ocular barrier. The glutathione-based ligands are conjugated to nanocontainers such as liposomes encapsulating the cGMPSs.


Find Patent Forward Citations

Loading…